Seeking Alpha

Questcor Pharmaceuticals (QCOR +2.1%) trades higher after TheStreetSweeper issues the first part...

Questcor Pharmaceuticals (QCOR +2.1%) trades higher after TheStreetSweeper issues the first part of a much-anticipated 2-part report. In the report, which Questcor has already gone to great lengths to denounce, TheStreetSweeper accuses Questcor of marketing its Acthar drug for unsanctioned uses, and of failing to establish a "firewall" between its marketing and R&D departments.
Comments (1)
  • hafmanhafhorse
    , contributor
    Comment (1) | Send Message
    I love the disclosure at the end of this report. They are banking on this greatly biased and exagerrated article to make them some serious dough. Already doing well off shorts. I wonder if they established this position prior to releasing info that this report was coming out.


    * Important Disclosure: Prior to the publication of this investigative report, TheStreetSweeper (through its members) established a short position in QCOR with the intention of profiting on any future declines in the stock price. Currently, TheStreetSweeper has sold a total of 44,466 shares of QCOR short at an average price of $41.06 a share. Going forward, TheStreetSweeper may choose to adjust the size of this investment – by increasing, decreasing or covering its short position in the stock – and will fully disclose the details of any future transactions as those trades occur.
    26 Jan 2012, 04:06 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: